Methyl Bromopyruvate | CAS:7425-63-0

We serve Methyl Bromopyruvate CAS:7425-63-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Methyl Bromopyruvate

Chemical Name:Methyl Bromopyruvate
CAS.NO:7425-63-0
Synonyms:Methyl Bromopyruvate
methyl 3-bromo-2-oxopropanoate
 
Physical and Chemical Properties:
Density 1.7±0.1 g/cm3
Boiling Point 186.8±23.0 °C at 760 mmHg
Molecular Formula C4H5BrO3
Molecular Weight 180.985
Flash Point 66.8±22.6 °C
Vapour Pressure 0.7±0.4 mmHg at 25°C
Index of Refraction 1.468
 
Specification:
Appearance:Light yellow liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Thiabendazole(CAS:148-79-8).



Contact us for information like Methyl Bromopyruvate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 3-bromo-2-oxopropanoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 3-bromo-2-oxopropanoate Use and application,methyl 3-bromo-2-oxopropanoate technical grade,usp/ep/jp grade.


Related News: Their pharmacological activity plays a direct role in the diagnosis, cure, mitigation, treatment, or prevention of disease.3'-Amino-2'-hydroxyacetophenone hydrochloride manufacturer Their pharmacological activity plays a direct role in the diagnosis, cure, mitigation, treatment, or prevention of disease.1-Phenylsemicarbazide supplier Their pharmacological activity plays a direct role in the diagnosis, cure, mitigation, treatment, or prevention of disease.1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea vendor It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.